{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:30:08Z","timestamp":1755801008752,"version":"3.44.0"},"reference-count":10,"publisher":"SMC Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"In light chain amyloidosis, a reduction in dFLC to below 40 mg\/l is a prerequisite for organ recovery as nearly half of the patients who achieve very good partial haematological responses have improvement in the function of the involved organ. We describe a patient who developed new-onset cardiac amyloidosis despite a post-treatment reduction in dFLC to <10 mg\/l.<\/jats:p>","DOI":"10.12890\/2023_003768","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T09:12:51Z","timestamp":1675933971000},"source":"Crossref","is-referenced-by-count":0,"title":["New-onset cardiac amyloidosis while in remission from systemic AL amyloidosis"],"prefix":"10.12890","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-9233","authenticated-orcid":false,"given":"Abiodun","family":"Idowu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Einstein Medical Center, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Tung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Chu","sequence":"additional","affiliation":[{"name":"Rush University Medical College, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamario","family":"Skeete","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agne","family":"Paner","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology\/Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tochukwu","family":"Okwuosa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Section of Cardio-Oncology, Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10397","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"10.12890\/2023_003768_ref1","doi-asserted-by":"crossref","unstructured":"
  • Imperlini E, Gnecchi M, Rognoni P, Sabido E, Ciuffreda MC, Palladini G, et al. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Sci Rep<\/em> 2017;7<\/strong>:15661. doi: 10.1038\/s41598-017-15424-3<\/li>","DOI":"10.1038\/s41598-017-15424-3"},{"key":"10.12890\/2023_003768_ref2","doi-asserted-by":"crossref","unstructured":"
  • Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood<\/em> 2017;130<\/strong>:632\u2013642. doi: 10.1182\/blood-2017-02-767475<\/li>","DOI":"10.1182\/blood-2017-02-767475"},{"key":"10.12890\/2023_003768_ref3","doi-asserted-by":"crossref","unstructured":"
  • Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, et al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis. Blood Cancer J<\/em> 2021;11<\/strong>:10. doi: 10.1038\/s41408-020-00397-w<\/li>","DOI":"10.1038\/s41408-020-00397-w"},{"key":"10.12890\/2023_003768_ref4","doi-asserted-by":"crossref","unstructured":"
  • Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart<\/em> 2017;103<\/strong>:1065\u20131072.<\/li>","DOI":"10.1136\/heartjnl-2016-310704"},{"key":"10.12890\/2023_003768_ref5","doi-asserted-by":"crossref","unstructured":"
  • Palladini G, Dispenzieri A, Gertz M, Kumar S, Wechalekar A, Hawkins P, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol<\/em> 2012;30<\/strong>:4541\u20134549. doi: 10.1200\/JCO.2011.37.7614<\/li>","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"10.12890\/2023_003768_ref6","doi-asserted-by":"crossref","unstructured":"
  • Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood<\/em> 2019;134<\/strong>:2271\u20132280. doi: 10.1182\/blood.2019000834<\/li>","DOI":"10.1182\/blood.2019000834"},{"key":"10.12890\/2023_003768_ref7","doi-asserted-by":"crossref","unstructured":"
  • Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G, et al. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcomes. Blood<\/em> 2017;130<\/strong>:625\u2013631. doi: 10.1182\/blood-2017-02-767467<\/li>","DOI":"10.1182\/blood-2017-02-767467"},{"key":"10.12890\/2023_003768_ref8","doi-asserted-by":"crossref","unstructured":"
  • Phelan D, Thavendiranathan P, Popovic Z, Collier P, Griffin B, Thomas J, et al. Application of a parametric display of two-dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiogr<\/em> 2014;27<\/strong>:888\u2013895. doi: 10.1016\/j.echo.2014.04.015<\/li>","DOI":"10.1016\/j.echo.2014.04.015"},{"key":"10.12890\/2023_003768_ref9","doi-asserted-by":"crossref","unstructured":"
  • Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood<\/em> 2010;116<\/strong>:3426\u20133430. doi: 10.1182\/blood-2010-05-286567<\/li>","DOI":"10.1182\/blood-2010-05-286567"},{"key":"10.12890\/2023_003768_ref10","doi-asserted-by":"crossref","unstructured":"
  • Harb SC, Haq M, Flood K, Guerrieri A, Passerell W, Jaber W, et al. National patterns in imaging utilization for diagnosis of cardiac amyloidosis: a focus on Tc99mpyrophosphate scintigraphy. J Nucl Cardiol<\/em> 2017;24<\/strong>:1094\u20131097. doi: 10.1007\/s12350-016-0478-3<\/li>","DOI":"10.1007\/s12350-016-0478-3"}],"container-title":["European Journal of Case Reports in Internal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/3768\/3417","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/3768\/3418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/3768\/3418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:06:53Z","timestamp":1755695213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/3768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.12890\/2023_003768","relation":{"has-manifestation":[{"id-type":"other","id":"1-95-3768-g3417","asserted-by":"subject"},{"id-type":"other","id":"1-95-3768-g3418","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-95","asserted-by":"subject"}]},"ISSN":["2284-2594"],"issn-type":[{"type":"electronic","value":"2284-2594"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"article-number":"5"}}